Accès gratuit
Numéro
Med Sci (Paris)
Volume 31, Numéro 12, Décembre 2015
Page(s) 1075 - 1077
Section Nouvelles
DOI https://doi.org/10.1051/medsci/20153112009
Publié en ligne 16 décembre 2015
  1. Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med 2013 ; 19 : 850–858. [CrossRef] [PubMed]
  2. Zona L, Turek M, Baumert TF, Zeisel MB. Hepatitis C virus internalization. Virologie 2013 ; 17 : 401–413.
  3. Harris HJ, Farquhar MJ, Mee CJ, et al. CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. J Virol 2008 ; 82 : 5007–5020. [CrossRef] [PubMed]
  4. Zona L, Lupberger J, Sidahmed-Adrar N, et al. HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. Cell Host Microbe 2013 ; 13 : 302–313. [CrossRef] [PubMed]
  5. Lupberger J, Zeisel MB, Xiao F, et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 2011 ; 17 : 589–595. [CrossRef] [PubMed]
  6. Sainz B, Barretto N, Martin DN, et al. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med 2012 ; 18 : 281–285. [CrossRef] [PubMed]
  7. Meuleman P, Hesselgesser J, Paulson M, et al. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology 2008 ; 48 : 1761–1768. [CrossRef] [PubMed]
  8. Lacek K, Vercauteren K, Grzyb K, et al. Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice. J Hepatol 2012 ; 57 : 17–23. [CrossRef] [PubMed]
  9. Vercauteren K, Van Den Eede N, Mesalam AA, et al. Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents. Hepatology 2014 ; 60 : 1508–1518. [CrossRef] [PubMed]
  10. Fofana I, Krieger SE, Grunert F, et al. Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology 2010 ; 139 : 953–964. e4. [CrossRef] [PubMed]
  11. Mailly L, Xiao F, Lupberger J, et al. Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody. Nat Biotechnol 2015 ; 33 : 549–554. [CrossRef] [PubMed]
  12. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998 ; 282 : 103–107. [CrossRef] [PubMed]
  13. Xiao F, Fofana I, Thumann C, et al. Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C. Gut 2015 ; 64 : 483–494. [CrossRef] [PubMed]
  14. Lu RY, Yang WX, Hu YJ. The role of epithelial tight junctions involved in pathogen infections. Mol Biol Rep 2014 ; 41 : 6591–6610. [CrossRef] [PubMed]
  15. Uprichard SL, Sainz B, Jr.. Inhibition of hepatitis C entry: too soon to dismiss while many are still being denied treatment. Gut 2015 ; 64 : 690–691. [CrossRef] [PubMed]
  16. Ray K. Hepatitis: Tightening the grip on clearing HCV infection. Nat Rev Gastroenterol Hepatol 2015 ; 12 : 249. [CrossRef] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.